XML 45 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Significant Accounting Policies - EPS and SBC (Details)
1 Months Ended 3 Months Ended
Jun. 13, 2017
shares
Dec. 09, 2016
shares
Jun. 30, 2017
item
$ / shares
shares
Feb. 28, 2017
item
$ / shares
shares
Aug. 31, 2016
item
$ / shares
shares
Mar. 31, 2018
USD ($)
employee
item
$ / shares
shares
Mar. 31, 2017
USD ($)
item
$ / shares
shares
Computation of Net Loss per Common Share              
Options outstanding to purchase common stock and unvested restricted stock           17,677,000 13,690,000
Common stock equivalents under treasury stock method for options and unvested restricted stock (in shares)           3,436,000 110,000
Shares issuable upon conversion of convertible notes (in shares) | item           501 23,878
Common stock equivalents under if-converted method for convertible notes (in shares)           501,000 23,878,000
Additional disclosure for options              
Cash received for exercise of stock options | $           $ 2,259,000  
Stock compensation expense (reduction) | $           3,700,000 $ 2,600,000
Estimated fair value of unvested employee awards, net of estimated forfeitures | $           $ 37,100,000  
Weighted average vesting period of unvested employee awards           3 years  
Stock options              
Weighted-average assumptions used to estimate the fair value of each stock option              
Dividend (as a percent)           0.00% 0.00%
Volatility (as a percent)           70.82% 66.89%
Risk-free interest rate (as a percent)           2.70% 2.03%
Expected life           6 years 6 years
Weighted-average grant date fair value (in dollars per share) | $ / shares           $ 10.55 $ 1.52
Number of Stock Options              
Outstanding at the beginning of the period (in shares)           11,971,000  
Granted (in shares)           4,465,000  
Exercised (in shares)           (421,000)  
Forfeited/Canceled (in shares)           (173,000)  
Outstanding at the end of the period (in shares)           15,842,000  
Weighted-Average Exercise Price              
Outstanding at the beginning of the period (in dollars per share) | $ / shares           $ 9.91  
Granted (in dollars per share) | $ / shares           10.55  
Exercised (in dollars per share) | $ / shares           5.37  
Forfeited/Canceled (in dollars per share) | $ / shares           12.83  
Outstanding at the end of the period (in dollars per share) | $ / shares           $ 10.18  
Additional disclosure for options              
Cash received for exercise of stock options | $           $ 2,300,000  
Stock options | Minimum              
Weighted-Average Exercise Price              
Exercised (in dollars per share) | $ / shares           $ 2.03  
Stock options | Maximum              
Weighted-Average Exercise Price              
Exercised (in dollars per share) | $ / shares           $ 12.21  
Restricted stock              
Stock-Based Compensation              
Exercise period     5 years 5 years 5 years    
Number of equal installments restrictions lapse | item     3 3 3    
Number of Restricted Stock              
Unvested at the beginning of the period (in shares)           2,319,000  
Vested (in shares)           (484,000)  
Unvested at the end of the period (in shares)           1,835,000  
Weighted-Average Grant Date Fair Value              
Unvested at the beginning of the period (in dollars per share) | $ / shares           $ 2.82  
Vested (in dollars per share) | $ / shares           2.52  
Unvested at the end of the period (in dollars per share) | $ / shares           $ 2.90  
Additional disclosure for options              
Stock compensation expense (reduction) | $           $ 0  
Restricted stock | Officers              
Number of Restricted Stock              
Awarded (in shares)     239,000 529,830 117,800    
Weighted-Average Grant Date Fair Value              
Awarded (in dollars per share) | $ / shares     $ 4.71 $ 2.47 $ 3.15    
2016 Plan              
Computation of Net Loss per Common Share              
Common stock equivalents under treasury stock method for options and unvested restricted stock (in shares)   14,250,000          
Stock-Based Compensation              
Number of employee share-based compensation plans | employee           1  
Additional shares authorized for issuance (in shares) 1,000,000            
Common stock authorized for issuance (in shares)   5,500,000          
2016 Plan | Stock options              
Weighted-average assumptions used to estimate the fair value of each stock option              
Number of group of awards for which expected term is calculated for and applied | item           1  
2016 Plan | Stock options | Maximum              
Stock-Based Compensation              
Vesting period           4 years  
Exercise period           10 years